Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: A therapeutic window relationship

Pharmacopsychiatry

Volumn 34, Issue 1, 2001, Pages 33-40

  Ulrich, S ^a   Northoff, G ^a   Wurthmann, C ^b   Partscht, G ^a   Pester, U ^a   Herscu, H ^a   Meyer, F P ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Psychiatric Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMITRIPTYLINOXIDE; NORTRIPTYLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSION; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; GAS LIQUID CHROMATOGRAPHY; HAMILTON SCALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, GAS; DEPRESSIVE DISORDER; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS;

EID: 0035141382     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15207     Document Type: Article

References (56)

1. Absence of evidence is not evidence of absence
2. Amitriptyline pharmacokinetics and clinical response: Free and total plasma amitriptyline and nortriptyline
3. Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response: A statistical review
4. Plasma concentration of amitriptyline and clinical response
5. Plasma levels, psychophysiological variables, and clinical response to amitriptyline
6. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels
7. Validation of a therapeutic plasma level range in amitriptyline treatment of depression
8. Short-term treatment of mood disorders with standard antidepressants
9. Amitriptyline plasma concentration and clinical effect
10. Pharmacokinetics and pharmacodynamics of amitriptyline in depression
11. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression
12. Amitriptyline and nortriptyline plasma levels and therapeutic response in depressed women
13. Monitoring of tricyclic antidepressant plasma levels and clinical response: A review of the literature. Part 1
14. Clomipramine dose-effect study in patients with depression: Clinical endpoints and pharmacokinetics
15. Predictive factors for therapeutic success in depressive syndrome
16. Plasma amitriptyline levels and its therapeutic effect in endogenous depression
17. Relation of plasma amitriptyline and nortriptyline levels to the therapeutic response in endogenous depression
18. Tricyclic antidepressants - Blood level measurements and clinical outcome: An APA task force report
19. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: Methods and first results for tricyclic antidepressants and SSRI
20. Psychosocial predictors of outcome in depression
21. The amitriptyline plasma levels and therapeutic response in patients with affective illness
22. Neuroleptic plasma levels: Methodological issues, study design, and clinical applicability
23. On the relationship of nortriptyline: Amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients
24. Imipramine and amitriptyline plasma concentrations and clinical response in major depression
25. Amitriptyline plasma levels and clinical response in primary depression: II
26. A clinical trial compairing sustained release amitriptyline (Amitriptyline, retard) and conventional amitriptyline tablets (Amitriptylin) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline
27. Relation of plasma levels and clinical response to amitriptyline in treating endogenous depression
28. Psychopharmaka
29. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels
30. Profound behavioral toxicity due to tricyclic antidepressants
31. A double-blind comparison of dothiepin and amitriptylin in patients with primary affective disorder: Serum levels and clinical response
32. Clinical response and plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients
33. Amitriptyline plasma concentrations and clinical response
34. Plasma levels and clinical improve ment - A comparative study of clomipramine and amitriptyline in depression
35. Early nonresponse to fluoxetine as a predictor of poor 8week outcome
36. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response
37. Levels of amitriptyline and its metabolites in the treatment of depression
38. Factors affecting the biphasic concentration - Effect relationships of tricyclic antidepressants
39. Therapeutic drug monitoring for antide pressants: Efficacy, safety, and cost effectiveness
40. Tricyclic antidepressant-induced seizures and plasma drug concentrations
41. Tricyclic-antidepressant-induced delirium and plasma drug concentration
42. Long-term treatment of mood disorders
43. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: A study of two fixed plasma levels
44. Plasma tricyclic drug levels in amitriptyline-treated depressed patients
45. Prediction of antidepressant response - Critical review and perspectives
46. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state
47. Sample size calculations for clinical pharmacology studies
48. Selection of neuroleptic dosage
49. Simultaneous determination of amitriptyline, nortriptyline and 4 hydroxylated metabolites in serum by capillary gas-liquid chromatography with nitrogenphosphorus selective detection
50. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: A review
51. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline
52. Variable dose studies provide misleading therapeutic windows
53. Amitriptyline plasma levels and therapeutic response
54. Serum concentrations of amitriptyline and its metabo lites and clinical effect in depressive patients